Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 11, 2021 2021-04-27
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (3) PROPOSED RE-APPOINTMENT OF AUDITORS; AND (4) NOTICE OF ANNUAL GENERAL MEETING 2021-04-27
GRANT OF SHARE OPTIONS 2021-04-23
VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTER PRESENTATION AT 2021 AACR ANNUAL MEETING 2021-04-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021 2021-04-09
VOLUNTARY ANNOUNCEMENT - APPOINTMENT OF CHIEF MEDICAL OFFICER AND CHIEF FINANCIAL OFFICER 2021-03-30
ADOPTION OF THE RESTRICTED SHARE AWARD SCHEME 2021-03-23
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 2021-03-23
DATE OF BOARD MEETING 2021-03-11
VOLUNTARY ANNOUNCEMENT - IND APPROVAL RECEIVED FOR A PHASE II CLINICAL TRIAL OF KN046 IN THE U.S. 2021-03-08

17 18 19 20 21 22 23